Search

Your search keyword '"Levy, Miriam T."' showing total 18 results
Start Over Author "Levy, Miriam T." Search Limiters Full Text
18 results on '"Levy, Miriam T."'

1. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

Author

Clark, Paul J., Valery, Patricia C., Ward, James, Strasser, Simone I., Weltman, Martin, Thompson, Alexander, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, and Roberts, Stuart K.

Published
2022
Full Text
View/download PDF

3. Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants

Author

Thompson, Alexander J., primary, Jackson, Kathy, additional, Bonanzinga, Sara, additional, Hall, Sam A.L., additional, Hume, Simon, additional, Burns, Gareth S., additional, Sundararajan, Vijaya, additional, Ratnam, Dilip, additional, Levy, Miriam T., additional, Lubel, John, additional, Nicoll, Amanda J., additional, Strasser, Simone I., additional, Sievert, William, additional, Desmond, Paul V., additional, Ngu, Meng C., additional, Sinclair, Marie, additional, Meredith, Christopher, additional, Matthews, Gail, additional, Revill, Peter A., additional, Littlejohn, Margaret, additional, Bowden, D. Scott, additional, Canchola, Jesse A., additional, Torres, Jason, additional, Siew, Philip, additional, Lau, Jasmin, additional, La Brot, Benjamin, additional, Kuchta, Alison, additional, and Visvanathan, Kumar, additional

Published
2023
Full Text
View/download PDF

4. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus

Author

Maharaj, Ashika D., primary, Lubel, John, additional, Lam, Eileen, additional, Clark, Paul J., additional, Duncan, Oliver, additional, George, Jacob, additional, Jeffrey, Gary P., additional, Lipton, Lara, additional, Liu, Howard, additional, McCaughan, Geoffrey, additional, Neo, Eu‐Ling, additional, Philip, Jennifer, additional, Strasser, Simone I., additional, Stuart, Katherine, additional, Thompson, Alexander, additional, Tibballs, Jonathan, additional, Tu, Thomas, additional, Wallace, Michael C., additional, Wigg, Alan, additional, Wood, Marnie, additional, Zekry, Amany, additional, Greenhill, Elysia, additional, Ioannou, Liane J., additional, Ahlenstiel, Golo, additional, Bowers, Kaye, additional, Clarke, Stephen J., additional, Dev, Anouk, additional, Fink, Michael, additional, Goodwin, Mark, additional, Karapetis, Christos S., additional, Levy, Miriam T., additional, Muller, Kate, additional, O'Beirne, James, additional, Pryor, David, additional, Seow, James, additional, Shackel, Nicholas, additional, Tallis, Caroline, additional, Butler, Nick, additional, Olynyk, John K., additional, Reed‐Cox, Kate, additional, Zalcberg, John R., additional, and Roberts, Stuart K., additional

Published
2022
Full Text
View/download PDF

7. Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

Author

Hall, Samuel A. L., primary, Burns, Gareth S., additional, Anagnostou, Despina, additional, Vogrin, Sara, additional, Sundararajan, Vijaya, additional, Ratnam, Dilip, additional, Levy, Miriam T., additional, Lubel, John S., additional, Nicoll, Amanda J., additional, Strasser, Simone I., additional, Sievert, William, additional, Desmond, Paul V., additional, Ngu, Meng C., additional, Angus, Peter, additional, Sinclair, Marie, additional, Meredith, Christopher, additional, Matthews, Gail, additional, Revill, Peter A., additional, Jackson, Kathy, additional, Littlejohn, Margaret, additional, Bowden, D. Scott, additional, Locarnini, Stephen A., additional, Visvanathan, Kumar, additional, and Thompson, Alexander J., additional

Published
2022
Full Text
View/download PDF

8. Monitoring quality of care in hepatocellular carcinoma: A modified delphi consensus

Author

Maharaj, Ashika D., Lubel, John, Lam, Eileen, Clark, Paul J., Duncan, Oliver, George, Jacob, Jeffrey, Gary P., Lipton, Lara, Liu, Howard, McCaughan, Geoffrey, Neo, Eu-Ling, Philip, Jennifer, Strasser, Simone I., Stuart, Katherine, Thompson, Alexander, Tibballs, Jonathan, Tu, Thomas, Wallace, Michael C., Wigg, Alan, Wood, Marnie, Zekry, Amany, Greenhill, Elysia, Ioannou, Liane J., Ahlenstiel, Golo, Bowers, Kaye, Clarke, Stephen J., Dev, Anouk, Fink, Michael, Goodwin, Mark, Karapetis, Christos S., Levy, Miriam T., Muller, Kate, O'Beirne, James, Pryor, David, Seow, James, Shackel, Nicholas, Tallis, Caroline, Butler, Nick, Olynyk, John K., Reed-Cox, Kate, Zalcberg, John R., Roberts, Stuart K., Maharaj, Ashika D., Lubel, John, Lam, Eileen, Clark, Paul J., Duncan, Oliver, George, Jacob, Jeffrey, Gary P., Lipton, Lara, Liu, Howard, McCaughan, Geoffrey, Neo, Eu-Ling, Philip, Jennifer, Strasser, Simone I., Stuart, Katherine, Thompson, Alexander, Tibballs, Jonathan, Tu, Thomas, Wallace, Michael C., Wigg, Alan, Wood, Marnie, Zekry, Amany, Greenhill, Elysia, Ioannou, Liane J., Ahlenstiel, Golo, Bowers, Kaye, Clarke, Stephen J., Dev, Anouk, Fink, Michael, Goodwin, Mark, Karapetis, Christos S., Levy, Miriam T., Muller, Kate, O'Beirne, James, Pryor, David, Seow, James, Shackel, Nicholas, Tallis, Caroline, Butler, Nick, Olynyk, John K., Reed-Cox, Kate, Zalcberg, John R., and Roberts, Stuart K.

Abstract

Although there are several established international guidelines on the management of hepatocellular carcinoma (HCC), there is limited information detailing specific indicators of good quality care. The aim of this study was to develop a core set of quality indicators (QIs) to underpin the management of HCC. We undertook a modified, two-round, Delphi consensus study comprising a working group and experts involved in the management of HCC as well as consumer representatives. QIs were derived from an extensive review of the literature. The role of the participants was to identify the most important and measurable QIs for inclusion in an HCC clinical quality registry. From an initial 94 QIs, 40 were proposed to the participants. Of these, 23 QIs ultimately met the inclusion criteria and were included in the final set. This included (a) nine related to the initial diagnosis and staging, including timing to diagnosis, required baseline clinical and laboratory assessments, prior surveillance for HCC, diagnostic imaging and pathology, tumor staging, and multidisciplinary care; (b) thirteen related to treatment and management, including role of antiviral therapy, timing to treatment, localized ablation and locoregional therapy, surgery, transplantation, systemic therapy, method of response assessment, and supportive care; and (c) one outcome assessment related to surgical mortality. Conclusion: We identified a core set of nationally agreed measurable QIs for the diagnosis, staging, and management of HCC. The adherence to these best practice QIs may lead to system-level improvement in quality of care and, ultimately, improvement in patient outcomes, including survival.

Published
2022

9. Additional file 1 of Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

Author

Clark, Paul J., Valery, Patricia C., Ward, James, Strasser, Simone I., Weltman, Martin, Thompson, Alexander, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, and Roberts, Stuart K.

Abstract

Additional file 1. Supplementary Table S1. List of Rx-Risk-V comorbidity categories with corresponding medicine groups and Anatomical Therapeutic Chemical (ATC), and ATC codes of medications dispensed to patients included in the Opera-C study. Supplementary Table 2. Prevalence of comorbidity categories included in the Rx-Risk-V according for First Nations Peoples and non-Indigenous Australians. Supplementary Table 3. Logistic regression analysis of factors associated with loss to follow-up among First Nations Peoples.

Published
2022
Full Text
View/download PDF

11. Migration route of Fasciola into the liver

Author

Lockart, Ian, Das, Amitabha, Merrett, Neil D, and Levy, Miriam T

Subjects
hepatology, parasitic diseases, gastroenterology, microbial pathogenesis, Case Report, gastrointestinal infections, Case Reports, liver imaging
Abstract

Humans usually acquire Fasciola infection by eating contaminated aquatic vegetation, such as watercress. After ingestion, Fasciola metacercariae excyst in the duodenum. In contrast to other liver flukes (Clonorchis and Opisthorchis) that migrate through the ampulla of Vater and ascend the biliary tree, Fasciola metacercariae penetrate the duodenal wall, migrate through the peritoneal cavity, and enter the liver. After a period of migrating randomly through the liver parenchyma, they eventually reach the larger biliary ducts and mature into adults. We present a case that illustrates this migration route of Fasciola.

Published
2018

13. Mo1458 - Response to Mycphenolate Mofetil in Patents with Autoimmune Hepatitis who Fail Standard Therapy is Predicted by Serum Gammaglobulin Levels but not Cirrhosis

Author

Nicoll, Amanda, primary, Roberts, Stuart K., additional, Lim, Ricky, additional, Mitchell, Joanne, additional, Weltman, Martin, additional, George, Jacob, additional, Wigg, Alan, additional, Stuart, Katherine, additional, Gow, Paul, additional, MacQuillan, Gerry, additional, Tse, Edmund, additional, Levy, Miriam T., additional, Sood, Siddharth, additional, Zekry, Amany, additional, Cheng, Wendy, additional, Mitchell, Jonathan, additional, Skoien, Richard, additional, Sievert, William, additional, Strasser, Simone, additional, and McCaughan, Geoff, additional

Published
2018
Full Text
View/download PDF

17. Migration route of Fasciola into the liver.

Author

Lockart, Ian, Das, Amitabha, Merrett, Neil D, and Levy, Miriam T

Subjects
FASCIOLA, GASTROENTEROLOGY, GASTROINTESTINAL diseases
Abstract

Humans usually acquire Fasciola infection by eating contaminated aquatic vegetation, such as watercress. After ingestion, Fasciola metacercariae excyst in the duodenum. In contrast to other liver flukes (Clonorchis and Opisthorchis) that migrate through the ampulla of Vater and ascend the biliary tree, Fasciola metacercariae penetrate the duodenal wall, migrate through the peritoneal cavity, and enter the liver. After a period of migrating randomly through the liver parenchyma, they eventually reach the larger biliary ducts and mature into adults. We present a case that illustrates this migration route of Fasciola. After ingestion, fasciola metacercariae penetrate the duodenal wall, migrate through the peritoneal cavity and enter the liver. After a period migrating randomly through the liver parenchyma, they eventually reach the larger biliary ducts and mature into adults. We present a case that illustrates this migration route of Fasciola. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. Migration route of Fasciola into the liver.

Author

Lockart I, Das A, Merrett ND, and Levy MT

Abstract

Humans usually acquire Fasciola infection by eating contaminated aquatic vegetation, such as watercress. After ingestion, Fasciola metacercariae excyst in the duodenum. In contrast to other liver flukes (Clonorchis and Opisthorchis) that migrate through the ampulla of Vater and ascend the biliary tree, Fasciola metacercariae penetrate the duodenal wall, migrate through the peritoneal cavity, and enter the liver. After a period of migrating randomly through the liver parenchyma, they eventually reach the larger biliary ducts and mature into adults. We present a case that illustrates this migration route of Fasciola.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results